share_log

Laidlaw & Co. Initiates Coverage On Bellerophon Therapeutics With Buy Rating, Announces Price Target of $35

Laidlaw & Co. Initiates Coverage On Bellerophon Therapeutics With Buy Rating, Announces Price Target of $35

Laidlaw & Co.以买入评级启动对Bellerophon Therapeutics的报道,宣布目标股价为35美元
Benzinga ·  2023/05/09 10:07

Laidlaw & Co. analyst Yale Jen initiates coverage on Bellerophon Therapeutics (NASDAQ:BLPH) with a Buy rating and announces Price Target of $35.

Laidlaw & Co. 分析师耶鲁·詹以买入评级开始对Bellerophon Therapeutics(纳斯达克股票代码:BLPH)进行报道,并宣布目标股价为35美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发